In situ immunization aims at generating antitumor immune responses through manipulating the tumor microenvironment. Based on recent advances in the understanding of antitumor immunity, we designed a three-step approach to in situ immunization to lymphoma: (1) Inducing immunogenic tumor cell death with the chemotherapeutic drug Doxorubicin (Dox). Dox antitumor immune responses can be generated locally by three-step therapy and merit further investigation as an immunotherapy for lymphoma patients.
Introduction
The goal of many forms of cancer immunotherapy is to overcome immunologic tolerance to tumor antigens and generate immune responses in the form of effector T cells (1) . In situ immunization is attractive because it utilizes the patient's unique tumor antigens by inducing tumor cell death in situ. This limits systemic drug toxicity and provides dendritic cells (DC) with a wide selection of tumor antigens to be presented to antigen-specific T cells (2, 3) .
Recent advances in our understanding of antitumor immunity suggest generating a potent, long-lasting antitumor response might benefit from a three step approach.
Step One -treatment would be delivered locally to induce tumor cell death and provide tumor antigens to DCs.
Step Two -activation of tumorspecific T cells by DCs would be enhanced.
Step Three -the activated T-cell response would be maintained so the systemic response can proceed unrestrained (2) . Doxorubicin (Dox) is an excellent candidate drug for enhancing tumor antigen uptake by DCs, and is routinely used for lymphoma (4) . Dox induces immunogenic cell death which stimulates an immune response in part by inducing surface expression of calreticulin, an "eat-me" signal that enhances phagocytosis of dying tumor cells by DCs (5-7).
In order for T cells to be activated by DCs, they must also receive a costimulatory signal, which can be supplied by toll-like receptor (TLR) agonists 4 (such as OX40) (8) (9) (10) . OX40 augments T-cell function and survival (10) (11) (12) . A stimulatory antibody that activates OX40 (anti-OX40) could thus be used to further activate tumor-specific T cells. We chose to focus on anti-OX40 due to its demonstrated synergistic activity with anti-CTLA-4, which enhances antitumor immune responses in murine lymphoma models (13) .
The activity of T cells is tightly regulated by checkpoints that control the magnitude of the immune response, exemplified by cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 is upregulated on activated T cells, and signaling via CTLA-4 reduces T-cell proliferation and activity (14) . In addition, CTLA-4 plays a central role in the suppressive effect of regulatory T cells (Treg) (15) . This provides strong rationale for including checkpoint blockade as a final step of in situ immunization.
While the use of Dox to induce immunogenic cell death is attractive for in situ immunization, an intratumoral injection of the soluble drug is not feasible due to its potent vesicant effects (16) . Poly(lactide-co-glycolide) or PLGA is an FDAapproved biodegradable polymer that is clinically used in surgical sutures and for controlled delivery of therapeutic drugs (17) . Following intratumoral injection, PLGA microparticles (MP) can provide sustained release of encapsulated molecules (18) into the tumor microenvironment without a vesicant effect. In addition, PLGA MPs are effective vaccine adjuvants. They activate the NALP3 inflammasome in DCs, which leads to IL1β secretion and the enhancement of innate and antigen-specific cellular immune responses (19 
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Based on this background, we hypothesized that a three-step approach to in situ immunization (Dox MPs given intratumorally combined with systemic anti-CTLA-4 and anti-OX40) can elicit a systemic curative adaptive immune response.
Materials and Methods

Mice and Cell Lines
Mice (BALB/c and C57BL/6 females, 6-8 weeks old) were purchased from Harlan Laboratories (Indianapolis, IN). All animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Iowa and complied with NIH Guidelines. A20 (murine BALB/c B-cell lymphoma), Raji (human Burkitt lymphoma B), and EL4 (murine C57BL/6 T-cell lymphoma) were purchased from American Type Culture Collection (ATCC, Manassas, VA). Epstein-Barr virus (EBV)-transformed B cells were previously generated per standard protocols (20, 21) . Subject informed consent was obtained in accordance with the Declaration of Helsinki under protocols approved by the institutional review board. Cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA) supplemented with 10% heatinactivated FCS (HyClone, Logan, UT), 100 U/mL penicillin, 100 μg/mL streptomycin, and 50 μM 2-ME (Gibco). All cell lines used were confirmed to be Mycoplasma free. No additional validation assays were performed.
Therapeutic Antibodies
Anti-CTLA4 (hamster IgG, clone UC10-4F10-11) and anti-OX40 (rat IgG1, clone OX86) were purchased from BioXCell (West Lebanon, NH). A20 were previously shown to lack surface expression of CTLA-4 and OX40 (13) . 
Generation of DCs
To generate murine bone-marrow-derived DCs, bone marrow cells were flushed from tibias and femurs of BALB/c mice, and mononuclear cells isolated using Ficoll gradient separation (Fico/Lite-LM, Atlanta Biologicals, Flowery Branch, GA). Cells were cultured in medium supplemented with 20 ng/mL each GM-CSF and IL4 (PeproTech, Rocky Hill, NJ) for 7 days. Non-adherent cells were harvested. Cells were > 70% DCs as determined by CD11c staining.
Viability Assays
The MTS assay for viability was used to determine the cytotoxic activity of Dox 
Rhodamine Particle Uptake
Uptake of particles by A20 and DCs was determined using rhodamine-loaded
MPs prepared similarly to Dox MPs. A20 and DCs were incubated for 24 h either alone or in a 1:1 mix with rhodamine-loaded MPs (0.5 µg/mL). Cells were washed and stained for CD11c -APC-Cy7 and CD19-APC (BD Biosciences (BD), San
Jose, CA). Uptake was assessed by flow cytometry using LSR II flow cytometer (BD) by gating on rhodamine + DCs (CD11c + ) and A20 (CD19 + ). 
CD4 and CD8 Depletion
Anti-CD4 (rat IgG2b, clone GK1.5) and anti-CD8 (rat IgG2b, clone 2.43) were purchased from BioXCell (West Lebanon, NH). Rat IgG (MP Biomedicals LLC, Santa Ana, CA) was used as isotype control. Antibodies (200 μg per injection) were administered one day before therapy and on Days +1, +4, +8, +12 and +18. CD4 and CD8 T-cell depletion was validated by flow cytometry (>99% depletion).
Flow Cytometric Analysis of Tumors and Lymphoid Tissue
Tumor and lymph node immune infiltrates were evaluated on Day 5 post therapy. Injected tumors, contralateral tumors and draining lymph nodes were harvested and single-cell suspensions surface stained with CD3-APC, CD4-FITC, CD8-PE-Cy7, IFNγ-PE, CD11b-PE, CD11c-APC-Cy7, CD44-APC, CD62L-PE (BD), Foxp3-APC and Gr-1-FITC (eBioscience, San Diego, CA) and fixed using BD Cytofix/Cytoperm.
Statistical Analysis
GraphPad Prism software, version 6.0 (San Diego, CA) was used to analyze tumor growth and to determine differences between groups using unpaired 2-tailed Student t tests or ANOVA (Bonferroni correction) where appropriate.
Survival curves were compared using the log-rank (Mantel-Cox) test. Upon injection into the tumor microenvironment, both tumor cells and immune cells would be exposed to Dox released from degrading MPs. Therefore, we evaluated the effect of Dox MPs and soluble Dox on DCs. Dox MPs were less cytotoxic to DCs than to A20 (24 h survival at 1.125 µg/mL Dox -23% for A20 versus 81% for DCs; p < 0.05). On the other hand, soluble Dox was equally cytotoxic to both (26% survival for A20 versus 19% for DCs; not statistically significant) ( Figure 1B) . By 72 h, lower concentrations of Dox MPs were still significantly more cytotoxic to A20 than to DCs (0% survival for A20 versus 74%
for DCs at 0.28125 µg/mL; p < 0.001), while higher concentrations were cytotoxic to both (0% survival for A20 versus 10% for DCs at 2.25 µg/mL; not statistically significant). This suggests careful titration of Dox MP doses will be important to identify the window where Dox MPs are toxic to malignant cells but not to DCs in the tumor.
Dox MPs are cytotoxic despite limited internalization
To evaluate whether MPs are internalized by cells, we utilized rhodamine- These mice remained tumor-free demonstrating a long-term memory response (data not shown).
Three-step therapy induces CD4-and CD8-dependent immune responses and requires all therapy components for maximum efficiency
We next evaluated the contributions of the various components of therapy. (Figure 5A ), confirming all components are needed for maximum efficacy.
We further examined the dose of Ab used in three-step therapy (referred to as Full Dose) by comparing it to Ab doses that were 1/4 th and 1/16 th the established dose (Supplementary Figure 5) . Efficacy was reduced with both lower doses, confirming that our established Ab dose (which is 50% of the reported dose (13)) was optimal in this model.
To confirm the role of T-cell subsets in the therapeutic response, CD4 or CD8 T cells were depleted. Depletion of either CD4 or CD8 T cells abolished the therapeutic effect ( Figure 5B ), confirming that the systemic antitumor effect was T cell-mediated.
Three-step therapy enhances T-cell infiltration into contralateral tumors
We next evaluated the tumor microenvironment histologically five days after initiation of therapy (Supplementary Figure 6) . While all tumors showed necrosis, mice that received Ab therapy had significantly more tumor necrosis than PBS control mice. Dox MP+Ab therapy and Ab therapy alone induced comparable necrosis, suggesting that the necrosis seen was due to antibody therapy rather than Dox MPs.
While Dox MP+Ab had no detectable effect on necrosis in the contralateral tumor, it did impact on T-cell infiltration ( Figure 10) .
Three-step therapy is effective in a murine EL4 lymphoma tumor model
The ability of Dox MPs to enhance the effect of Ab therapy was also evaluated in the EL4 T-cell lymphoma model. Our prior studies demonstrated MPs containing higher doses of Dox are needed to effectively treat EL4, and that EL4 grows too rapidly for a two-sided model to be valuable (26) . We therefore evaluated the effect of three-step therapy on EL4 by treating a single tumor with Dox MPs at a dose of 25 µg Dox. Using this approach, Dox MP+Ab significantly reduced EL4 tumor burdens and resulted in 50% long-term survival. None of the mice receiving Ab therapy alone survived (Supplementary Figure 11) .
Discussion
With the growth of scientific insight into pathways that regulate the immune system and cancer, we can now more intelligently design and combine immunotherapies that work in different ways to overcome deficiencies of single therapies (27) . One attractive approach is to use in situ therapy with MPs to manipulate the tumor microenvironment in a manner that breaks tolerance and allows development of a robust immune response. The number of variables that needs to be evaluated when trying to optimize the promise of such a multistep approach is considerable. Here, we address many of these variables, and demonstrate this approach has promising immunologic and therapeutic effects. 
An ideal in situ immunization approach would deliver localized and effective drug concentrations into the tumor with low systemic toxicity (23) . Given its long history of FDA-approved use for biomedical applications and its biocompatibility (28), PLGA was seen as an excellent candidate polymeric vehicle for controlled release of Dox from MPs into the tumor.
We first optimized formulation parameters affecting particle size, loading, and release. 1-µm PLGA MPs have been shown to be more effective than 200 nm, 500 nm, and 5-µm particles as vaccine adjuvants (29) . The relatively low dose of Dox MPs, coupled with their sustained release, proved to be a safe combination for DCs that survived well in vitro and in situ despite internalizing the particles. (13, 34, 35) . Thus, the finding that both CD4 and CD8 cells are needed for an optimal antitumor effect in our studies was not surprising.
To investigate how the addition of Dox MPs to Ab therapy is modulating the intratumoral T-cell response, we examined the Treg population and found no effect of three-step therapy on the percent of Tregs. On the other hand, we found enhanced CD4 T-cell infiltration in contralateral but not injected tumors. These The increase in pathologically-detectable destruction of established tumors, as reflected by tumor necrosis, was seen with both the three-step therapy and Ab therapy. Quantifying necrosis within a tumor sample is difficult, and it was not possible to determine definitively whether three-step therapy enhanced necrosis, however the improved overall outcome suggests this is the case. Similar responses were seen in tumor samples from patients receiving immunotherapy, and may thus be reflective of the ongoing antitumor immune response (36) .
We also validated the efficiency of three-step therapy in the EL4 tumor model. The three-step design is complex, and the number of agents that could be evaluated for each step is extensive. Other approaches, such as local radiation, can be used to induce local immunogenic cell death (37) . Anti-OX40 can be substituted with other immunostimulatory antibodies targeting TNFR costimulatory molecules, including CD40 and CD137 or TLR agonists such as CpG 
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checkpoint blockade such as anti-PD-1 (38) . Alternatives related to the dosing and timing of how these agents could be used together leads to an almost endless number of possible combinations. The studies reported here highlight the value of the three-step approach rather than demonstrate that the specific agents or regimen used is superior to other regimens.
Indeed, given that Dox MPs are not clinically approved, a faster translation to the clinic could require approximation of our design using readily-available reagents such as liposomal Dox (Doxil ® ). In preliminary studies, we found Dox MPs were more effective than liposomal Dox in inducing systemic immune responses in mice (data not shown) which is why they were used. PLGA particles were shown to be superior to liposomal formulations in inducing cellular immune responses, which was attributed to their sustained release rather than an adjuvant effect of the synthesizing material (39) . Indeed, liposomal Dox is currently under consideration for a clinical trial exploring a combination similar to that outlined in this report. While liposomal Dox would provide a more direct path toward clinical evaluation, studies comparing Dox MPs to liposomal Dox in human cell lines would also be informative.
In conclusion, recent advances in our understanding of cancer immunotherapy suggest rational combined approaches will be keys to enhancing efficacy. We evaluated a three-step approach to in situ immunization using biodegradable Dox MPs, anti-CTLA-4 and anti-OX40 (Figure 7) . Further preclinical evaluation of this promising therapeutic strategy in other types of cancer is ongoing, as are plans to translate these findings to the clinic. 5A. Mice (7-8/group) were treated and observed similarly to that described for 
